logo

For the Inventor, By the Inventor

Lorrach, Germany

Ralf Koberstein

This inventor holds 18 USPTO granted patents and 9 published patent applications and 16 EPO patents. Top assignees: Actelion Pharmaceuticals Ltd, Other. Active years: 2004-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ralf Koberstein. Retrieved from https://idiyas.com/inventor/ralf-koberstein

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 

% Patents Active = 16.7

 

Average Co-Inventor Count = 5.4

ph-index = 9

Forward Citations = 174(Granted Patents)


Location History:

  • Lörrach, DE (2004 - 2012)
  • Lorrach, DE (2010 - 2012)
  • Lorrach, GE (2012)

Company Filing History:

goldMedal17 out of 217 
 
Actelion Pharmaceuticals Ltd
 patents
silverMedal1 out of 834,453 
Other
 patents

Years Active: 2004-2012

Loading Chart...
Loading Chart...
18 patents (USPTO):Explore Patents
1. 8288435 - 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists (2012-10-16),
2. 8288429 - 2-aza-bicyclo[3.3.0]octane derivatives (2012-10-16),
3. 8288411 - Pyrrolidines and piperidines as orexin receptor antagonists (2012-10-16),
4. 8236964 - Thiazolidine derivatives as orexin receptor antagonists (2012-08-07),
5. 8236801 - 2-aza-bicyclo[2.2.1]heptane derivatives (2012-08-07),
6. 8133901 - 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors (2012-03-13),
7. 8106215 - 3-aza-bicyclo[3.3.0]octane compounds (2012-01-31),
8. 8063099 - Trans-3-aza-bicyclo[3.1.0]hexane derivatives (2011-11-22),
9. 8003654 - N-glycinsulfonamide derivatives and uses as orexin receptor antagonists (2011-08-23),
10. 7994336 - Azetidine compounds as orexin receptor antagonists (2011-08-09),
11. 7834028 - Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists (2010-11-16),
12. 7763638 - Substituted 1,2,3,4-tetrahydroisoquinoline derivatives (2010-07-27),
13. 7538109 - Quinoxalin-3-one derivatives as orexin receptor antagonists (2009-05-26),
14. 7435815 - Sulfonylamino-acetic acid derivatives (2008-10-14),
15. 7279578 - Sulfonylamino-acetic acid derivatives (2007-10-09),

Title: Ralf Koberstein: Innovator in Medicinal Chemistry

Introduction

Ralf Koberstein is a prominent inventor based in Lorrach, Germany. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that act as orexin receptor antagonists. With a total of 18 patents to his name, Koberstein's work has the potential to impact therapeutic approaches for various medical conditions.

Latest Patents

Among his latest patents, Koberstein has developed 2-aza-bicyclo[3.3.0]octane derivatives. This invention relates to compounds of Formula (I), which are described in detail in the patent documentation. These compounds, along with their pharmaceutically acceptable salts, are proposed for use as medicaments, specifically targeting orexin receptors. Another notable patent involves pyrrolidines and piperidines, which also serve as orexin receptor antagonists. The compounds in this patent are similarly defined by a specific formula and are intended for medicinal applications.

Career Highlights

Koberstein has worked with Actelion Pharmaceuticals Ltd, where he has been involved in groundbreaking research and development. His expertise in medicinal chemistry has allowed him to contribute to innovative solutions in the pharmaceutical industry.

Collaborations

Throughout his career, Koberstein has collaborated with notable professionals in the field, including Hamed Aissaoui and Thierry Sifferlen. These collaborations have further enriched his research and development efforts.

Conclusion

Ralf Koberstein's contributions to medicinal chemistry, particularly in the area of orexin receptor antagonists, highlight his innovative spirit and dedication to advancing medical science. His extensive patent portfolio reflects his commitment to developing effective therapeutic solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…